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Abstract
The Epstein-Barr virus (EBV) encoded Latent Membrane Protein 1 (LMP1) has been shown to increase the
expression of promyelocytic leukemia protein (PML) and the immunofluorescent intensity of promyelocytic
leukemia nuclear bodies (PML NBs). PML NBs have been implicated in the modulation of transcription and the
association of reporter plasmids with PML NBs has been implicated in repression of reporter activity. Additionally,
repression of various reporters in the presence of LMP1 has been noted. This study demonstrates that LMP1
suppresses expression of reporter activity in a dose responsive manner and corresponds with the LMP1 induced
increase in PML NB intensity. Disruption of PML NBs with arsenic trioxide or a PML siRNA restores reporter activity.
These data offer an explanation for previously conflicting data on LMP1 signaling and calls attention to the
possibility of false-positives and false-negatives when using reporter assays as a research tool in cells expressing
LMP1.
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Background
The Epstein -Barr Virus (EBV) encoded Latent Mem-
brane Protein 1 (LMP1) is required for the immortaliza-
tion of B-cells by EBV, and LMP1 acts as a bona fide
oncogene in transforming rodent fibroblast in vitro
[1-4]. Structurally, LMP1 is composed of a cytoplasmic
N-terminus, six transmembrane domains and a cytoplas-
mic C-terminus [5]. The C-terminus contains two major
signaling domains, C-terminus activating regions 1 and
2 (CTAR 1, CTAR 2), which activate NF-B [6-8] and
p38 [9] signaling pathways through interaction with the
effector proteins tumor necrosis factor receptor-asso-
ciated factors and tumor necrosis factor receptor-asso-
ciated death domain. LMP1 can also activate ERK
signaling through the CTAR 1 domain [10-13], and c-
jun N-terminus kinase (JNK) through the CTAR 2
domain [14,15] in an NF-B independent manner. In
addition, constitutive activation of the JAK/STAT path-
way by LMP-1 has been mapped to 2 Janus kinase bind-
ing sites in the region between CTAR 1 and 2 [16,17].
We have previously shown that LMP1 increases the
immunofluorescent intensity of promyelocytic leukemia
nuclear bodies (PML NBs) through increased expression
of PML protein [18]. The PML NB is a multifunctional
proteinaceous nuclear organelle that has been implicated
in transcriptional regulation, telomere maintenance, and
regulation of apoptosis [19-23]. Although formation of
the PML NB is dependent on the PML protein, more
than one hundred different proteins have been shown to
be recruited to PML NBs, which supports functional
heterogeneity of the this nuclear organelle [24]. PML is
induced by type I and II interferons [25,26] and has
been implicated in antiviral defense [27]. Further, the
conserved disruption of PML NBs by alpha, beta, and
gamma herpes viruses during lytic reactivation attests to
the importance of PML NBs in transcription and the
herpesviral lifecycle [28-32]. Increased expression of
PML contributes to the maintenance of EBV latency,
while arsenic trioxide or PML siRNA disruption of PML
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NBs results in EBV lytic replication, affirming the role of
PML in selective transcriptional control [18].
The firefly luciferase gene from Photinus pyralis has
been sequenced, and when coupled to promoters of
interest, has been a valuable tool to study transcription
regulators [33,34]. The rational of the reporter assay
assumes that experimental conditions modulate gene
expression through binding of transcription complexes
to the promoter sequence of interest (e.g.: through acti-
vation of transcription factors, etc.). However, expres-
sion of LMP1 within the cell or association with PML
NBs has been shown to affect reporter activity
[19,35,36]. In this study, we show that LMP1-mediated
suppression of reporter activity is attributable to the
upregulation of PML and PML NBs. Disruption of PML
NBs by arsenic trioxide or PML siRNA restored reporter
activity. These data posit a plausible explanation to
reconcile previous conflicting data on LMP1 signaling
activity and alerts researcher to the possibility of false-
positives and false-negatives when using reporter assays
as screening tools.
Results
LMP1 suppresses the expression of reporter plasmids
Expression of LMP1 in A549 cells has been shown to
increase transcription of the endogenous MMP9 gene
and MMP9 protein levels in an NFB dependent man-
ner [37]. Consistent with previous studies, expression of
LMP1 increased the levels MMP9 in condition medium
(Figure 1A). In contrast, when a reporter construct con-
taining a 700 bp fragment of the MMP 9 promoter
region was co-transfected with the LMP1 expression
plasmid, LMP1 expression resulted in suppression of
reporter activity (Figure 1B). Selective suppression of
reporter activity by LMP1 has been previously reported
[35], though suppression of reporter activity in that
study correlated with suppression of endogenous pro-
moter activity. To further investigate the LMP1 induced
disparity between activity on endogenous and exogenous
promoters, A549 cells were co-transfected with the
LMP1 expression vector and a series of reporter plas-
mids. Based on previous reports, LMP1 expression was
expected to increase AP-1 and NF-B responsive repor-
ter activity while having no effect on the constitutive
reporters FOP Flash, SV40, pGL3-Control and pRL-TK
(renilla luciferase driven by the HSV1 thymadine kinase
promoter). LMP1 expression suppressed reporter activ-
ity in assays utilizing the LEF/TCF responsive TopFlash
reporter, the mutated LEF/TCF control reporter (Fop-
Flash), an NF-B responsive reporter, an AP1 responsive
luciferase reporter construct, and a viral promoter driv-
ing b-galactosidase (SV40) (Figure 1B).
To test whether the suppression of reporter activity by
LMP1 was specific to A549 cells, a similar series of
reporter assays were conducted in nasopharyngeal carci-
noma cells (CNE-1). LMP1 expression resulted in sup-
pression of reporter activity in each of the constructs
utilized (Figure 1C).
Figure 1 LMP1 suppresses expression of exogenous DNA. A)
A549 and CNE1 cells retrovirally transduced with LMP1 expression
or empty vector were cultured for 24 hrs. Conditioned medium was
used to measure MMP9 by gelatin zymography. B) 7.5 × 104 A549
cells or C) CNE1 cells were co-transfected with 100 ng of the
indicted luciferase construct and either 300 ng of empty vector or
LMP1 expression vector. Cells were harvested at 24 hours post
transfection.
Sides et al. Virology Journal 2011, 8:461
http://www.virologyj.com/content/8/1/461
Page 2 of 9
LMP1 suppression of Reporter plasmids is LMP1 dose
responsive
To determine that the effect was not an artifact of trans-
fection efficiency, A549 cells were co-transfected with a
constant amount of the NFB responsive reporter along
with increasing levels of the LMP1 expression vector
(Figure 2A). Very low levels of LMP1 resulted in a mod-
est increase in luciferase activity whereas increasing
levels of LMP1 resulted in graded suppression of repor-
ter activity. Reporter activity suppression was also
observed when the constitutive firefly construct pGL3
(Figure 2B), the constitutive renilla luciferase reporter
containing the HSV1 thymidine kinase promoter (Figure
2C), or the firefly luciferase LEF/TCF responsive Top-
Flash reporter (Figure 2D) were employed in a dual luci-
ferase assay. Notably, when the LEF/TCF responsive
data was normalized to the RL-TK data, an artifactual
activation was observed (Figure 2E).
Arsenic trioxide disrupts PML NBs in LMP1 positive cells
Arsenic trioxide (ATO) has been shown to induce polyu-
biquitination dependent proteasomal degradation of PML
by directly binding to the conserved RBCC domain
[38-40]. To determine the minimal level of ATO needed
to disrupt PML NBs in A549 cells, A549 cells retrovirally
transduced with LMP1 expression vector or the backbone
vector were treated with 1-100 nM ATO for 24 hours and
PML NBs were imaged by immunofluorescence. Treat-
ment with ATO produced disruption of PML NBs in a
dose dependent manner with complete disruption at a
concentration of 10 nM (Figure 3A), whereas cytotoxcicity
was noted at doses above 100 nM. To investigate whether
intact PML NBs are required for LMP1 induced plasmid
silencing, A549 cells transduced with an LMP1 retrovirus
were transfected with the constitutive reporter pGL3 and
treated with varying doses of ATO (Figure 3B). An
increase in luciferase activity was seen with the addition of
ATO at 1.0 and 10.0 nM concentrations, corresponding
with the loss of PML NB immunofluorescence intensity.
ATO restored reporter activity in LMP1 positive cells
To assess the effects of LMP1 expression level on the
ability of ATO to restore reporter activity, LMP1 trans-
duced A549 cells were assessed for LMP1 expression
(Figure 3C). A549 cells expressing higher and lower
levels of LMP1 or transduced with the empty vector
were transfected with the constitutive reporter pGL3
Control and treated with 8 nM ATO for 24. ATO treat-
ment resulted in a 5-fold increase in reporter activity in
A549 <LMP1> HI cells, though this level was below that
of control. In the A549 <LMP1> Lo cells, luciferase
activity was completely restored (Figure 3D).
Specific disruption of PML NBs by PML specific siRNA
restores reporter activity
To preclude possible off target effects by ATO in luci-
ferase restoration assays, PML NBs were disrupted using
siRNA specifically targeted to the PML transcript. Treat-
ment of A549 cells retrovirally transduced with the
LMP1 expression vector along with PML specific siRNA
resulted in marked though not complete disruption of
PML NBs (Figure 4A). In luciferase assays utilizing a
viral (pGL3Control and pRL-TK) and cellular (pAP1-
Luc and p3TP-Lux) reporters transfected into LMP1
positive A549 cells, the addition of PML specific siRNA
resulted in a 7 to 17 fold increase in luciferase activity
compared to control siRNA (Figure 4B).
Discussion
A previous report demonstrated that LMP1 induces sup-
pression of some, but not all, reporter constructs, and that
reporter suppression correlated with suppression of endo-
genous gene expression [35]. In the present study, the sup-
pression of reporter activity was independent of the
specific promoter used. Importantly, the MMP9 reporter
activity did not correlate with the observed LMP-1-
mediated robust increase in endogenous MMP9 protein
expression. The major activation elements in the MMP9
gene promoter are AP-1 and NF-B [41], and LMP1 has
been shown to increase the expression of endogenous
MMP9 in an NF-B dependent manner [37]. Co-transfec-
tion of either AP-1 or NF-B responsive reporters along
with LMP1, however, resulted in suppression of both
reporters. Since LMP1 induces activation of NF-KB signal-
ing through both CTAR1 and CTAR2 (by interacting with
TRAF and TRADD) [42] it is predicted that LMP1 should
increase NK-B reporter activity in a dose responsive
manner. As shown in Figure 2, however, NF-B depen-
dent reporter activity demonstrated a biphasic response
curve resulting in suppression with moderate LMP1 input
amounts and abrogation of reporter activity at higher
input amounts. These findings may have significant bear-
ing upon the EBV literature. Recently, conflicting data as
to the role of LMP1 in the transcription of LEF/TCF
responsive genes have been reported based on results
from reporter assays [43-45]. The data contained herein
may help explain the differences in reported results. When
the TopFlash reporter data are normalized to RL-TK in
dual luciferase reporter assays, these normalized results
are inverse to the un-normalized results and show activa-
tion. Similarly, reports of LMP1 suppression of TGF-b1
responsive PAI-1 reporter constructs suggested suppres-
sion of PAI-1 gene transcription [46,47] while a previous
study reported upregulation of PAI-1 by LMP1 [37,48].
The observed LMP1 suppression of reporter constructs
used in this study was independent of the promoter as
even the activity of minimal and constitutive promoters
was suppressed. Taken together, these data suggest the
possibility of false positives and false negatives when utiliz-
ing luciferase assays as a screening tool for LMP1
signaling.
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The maintenance of viral latency by LMP1 has been
shown to be dependent on upregulation of PML and
PML NBs [18]. PML NBs have been implicated in tran-
scriptional control [22] as well as the creation of an
antiviral state [27]. Expression of LMP1 increased
transcription of the endogenous MMP9 gene while sup-
pressing activity of an MMP9 promoter driven luciferase
construct, demonstrating selectivity for LMP1-mediated
suppression of ectopic DNA. The suppression of ectopic
DNA activity by LMP1 is dependent on upregulation of
Figure 2 LMP1 suppression of reporter activity is dose responsive. 7.5 × 104 A549 cells were co-transfected with 100 ng of A) an NF-kB
responsive reporter or B) the constitutive reporter pGL3-comtrol and the indicated amount of the LMP1 expression vector. The total amount of
DNA in each well was held constant by addition of empty backbone vector. C & D) In a dual luciferase assay, 7.5 × 104 A549 cells were co-
transfected with the TopFlash firefly and the Thymidine Kinase renilla luciferase construct and the indicated amount of the LMP1 expression
vector. 10 mM LiCl was used as a positive control. Cells were harvested at 24 hours post transfection. E) Top-Flash luciferase activity normalized
to RL-TK expression.
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Figure 3 Arsenic trioxide restores expression of exogenous DNA. A) ATO treatment disrupts PML NB. Retrovirally transduced A549 cell
expressing LMP1 or a hygromycin resistance cassette (control) were treated for 24 hours with the indicated concentration of ATO and stained
for PML (green). Nuclei are stained with DAPI (blue) at original magnification of 600X. B) ATO restores luciferase activity in a dose responsive
manner. 7.5 × 104 A549 < LMP1> Hi cells were transfected with 100 ng NF-kB responsive luciferase and treated with the indicated concentration
of ATO for 24 hours. C) LMP1 is differentially expressed in separate retroviral transductions. A549 cells were retrovirally transduced with backbone
vector expressing only the hygromycin resistance cassette or LMP1 expression vector. Western blot analysis of whole cell lysate of control cells
and two separate LMP1 vector transductions; 35 ug of protein was loaded per well. Beta actin was used as a loading control. D) ATO-induced
restoration of exogenous DNA expression is LMP1 dose responsive. 7.5 × 104 A549 cells retrovirally transduced with backbone vector or 2
separate retroviral transductions differentially expressing LMP1 were transfected with pGL3_Luc and treated with 8 nM ATO for 24 hours.
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PML NB, as supported by the rescue of luciferase activ-
ity with the addition ATO or PML siRNA. The role of
PML NB in transcriptional control of certain gene sets
has been explored, and data suggests multiple mechan-
isms are involved [19,22,23]. Taken together, these data
suggest PML NB’s antiviral activity occurs through sup-
pression of ectopic DNA expression.
Materials and methods
Cell Culture and Transfection
A549 cells were obtained from ATCC. CNE1 cells
were obtained from Samuel H. Speck, (Emory Univer-
sity, Atlanta, Georgia, USA) and have been previously
described [49]. All cells were maintained in Dulbec-
co’s minimal essential medium (Invitrogen, Eugene
Oregon) supplemented with 10% fetal bovine serum
(Gemini Bio-Products, West Sacramento CA) and 10
units/ml penicillin and 10 μg/ml streptomycin (Invi-
trogen). For transient transfection and luciferase
experiments, cells were plated in 24-well plates at an
initial density of 7.5 × 104 cells per well and trans-
fected with Lipofectamine (Invitrogen) optimized with
Plus reagent (Invitrogen) according to the manufac-
turer’s instructions. During chemical treatment, A549
and A549 derived cells were cultured in DMEM +
0.5% FBS.
Figure 4 siRNA targeted disruption of PML NBs restores MMP9 reporter activity. A) A549 cells retrovirally transduced with either the
backbone or LMP1 expression vector were transfected with either control siRNA or siRNA directed towards the PML transcript. PML NB intensity
(green) was assessed at 24 hours post transfection. LMP1 is shown in red, DAPI nuclear counter-stain is shown in blue; original magnification of
400X. B) 7.5 × 104 A549 cells were reverse transfected with either the control siRNA or siRNA directed towards the PML transcript at plating.
After 24 hours, the cells were co-transfected with 100 ng of the indicated luciferase construct and 300 ng of LMP1 expression vector. Cells were
harvested at 24 hours post transfection and luciferase activity assessed.
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Generation of Retrovirally Transduced Cells
Generation of the pEhyg*FLAG*LMP1*wt vector and
retroviral transduction of cells have previously been
described [50]. Retrovirally transduced cells were
maintained in 250 μg/ml hygromycin until 24 hours
prior to plating for experiments. In separate infections,
differential LMP1 expression was characterized and the
two cell lines designated A549 <LMP1> Hi and A549
<LMP1> Lo; control cells were designated A549
<pEhyg>.
Plasmids and Reagents
Arsenic trioxide (ATO) (Sigma Aldrich, St Louis Mo,
#311383) was used at a concentration of 10 nM for
treatment of A549 derived cell lines. Lithium Chloride
(Sigma) was used at a concentration of 10 mM. The
pcDNA*Flag*LMP1*wt vector was kindly provided by
Nancy Rabb-Traub (UNC-Linberger Cancer Institute).
Dominant active IB plasmid has been previously char-
acterized [51]and was a gift from Dean Ballard (Van-
derbilt University Medical School, Nashville, TN,
USA). The 700 bp promoter region MMP9 luciferase
construct (MMP9-Luc) containing two AP-1 respon-
sive sites and one NF-B responsive site was a gift
from Douglas Boyd (MD Anderson Cancer center,
Houston, TX, USA), and has been previously charac-
terized [52]. The LEF/TCF responsive reporter pSu-
per8TopFlash_Luc containing eight LEF/TCF
responsive elements and the control, pSuper8Fop-
Flash_Luc containing mutations in these sites were
obtained from AddGene (http://www.addgene.org/)
and have been previously described [53]. The NF-B
responsive reporter construct (pNFB_Luc), control
reporter plasmids pGL-3_Control luciferase and
pSV40_bGal b-galactosidase were obtained from Pro-
mega (Madison, Wisconsin). The pAP1_Luc reporter
construct containing multiple AP1 responsive
sequences fused to a TATA-like promoter was
obtained from Clonetech (Mountain View, CA).
Luciferase Assays
For luciferase assays, 7.5 × 104 cells were plated in each
well of a 24-well plate, transiently transfected as stated
above with 100 ng of the specified reporter plasmid per
well, and harvested at 24 hours. For co-transfection and
plasmid dose response assays, the total amount of DNA
was held constant between wells. Treatment with 10
mM LiCl for four hours was used as a positive control
for Top-Flash luciferase activity. Luciferase activity was
quantified using the Luciferase Assay System (Promega
# E1500) according to manufacturer’s protocol, using a
single tube luminometer (EG&G Berthold Lumat
LM9507) programmed for a two second delay followed
by a ten second read.
Western Blots
Nuclear and membrane fractions of indicated cell lysates
were separated using the Qproteome Cell Compartment
Kit (Qiagen, Valencia, CA, #37502) according to the
manufacturer’s directions. Briefly, 5 × 106 cells were
harvested in proprietary extraction buffer, separated by
centrifugation, and the cytosolic fraction (supernatant)
was removed. The remaining pellet was resuspended in
proprietary extraction buffer, separated by centrifuga-
tion, and the membrane fraction (supernatant) was
removed. After nuclease treatment, the pellet was resus-
pended in 500 ul of proprietary extraction buffer, sepa-
rated by centrifugation, and the nuclear fraction
(supernatant) was removed. Nuclear (PML and mem-
brane (LMP1) fractions were combined with 4X
Laemmli Buffer ( 240 mM Tris, 8% SDS, 40% glycerol,
10% 2-mercaptoethanol, 0.02% bromophenol blue) and
30 micrograms of protein per well were loaded in a 10
well NuPage Mops 4-12% gradient minigel (Invitrogen).
Proteins were separated by electrophoresis at 130 V for
1.5 hours. Separated proteins were transferred for 1.5
hours at 30V to PDVF membrane (Invitrogen). Protein
transfer was verified by Ponsou-S staining. Membranes
were blocked in 5% BSA in PBST for 1hr prior to appli-
cation primary antibody overnight at 4°C while shaking
at 55 rpm. Rabbit polyclonal primary antibody to PML
(Santa Cruz Biotechnologies, Santa Cruz, CA, #sc-5621)
was used at a dilution of 1:200. Rabbit polyclonal pri-
mary antibody to b-Actin (Cell Signaling, #4967) was
used at a dilution of 1:1000. Mouse monoclonal primary
antibody to LMP1 was (B D Bioscience, Bedford, MA,
#559898) used at a dilution of 1:1000. The secondary
antibodies were fluorophore conjugated IRDye 680 goat
anti-mouse IgG (LiCor Lincoln, NE, #926-32220) or
IRDye 800CW goat anti-rabbit IgG (LiCor, #926-32211),
and were used at a dilution of 1:15,000. Membranes
were imaged using an Odyssey Infrared Imaging System
(LiCor).
Immunofluorescence Microscopy
A549 cells were plated on 8-chambered Lab-Tek slides
at 2 × 104 cells per well; chemical treatment began 24
hours after plating. At specified time points, cells were
rinsed twice with PBS and fixed in 4% Paraformaldehyde
(freshly diluted from 16%, Electron Microscopy Science,
Hatfield, PA) for 10 min at room temperature. The cells
were then rinsed twice with PBS and permeabilized with
0.5% Triton X100 (Sigma) in PBS for 15 min at room
temperature. Primary antibodies were applied overnight
in a humidified chamber at 4° C. Following 3 rinses in
PBS, secondary antibodies (1:500 dilution) were applied
for 1 hour at room temperature. The chambers were
removed and Vectashield with DAPI (Vector Labora-
tories, Burlingame, CA # H1200) was applied with a
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cover slip mount. The slides were imaged using a Nikon
Eclipse 80i microscope and a SensiCam QE camera
(Cooke Corporation) and IPLab V3.65a software (Scana-
lytics). Cells were grown on the same chamber slide and
were exposed to the same antibody concentration and
wash times. Exposure conditions were optimized for the
brightest field of the specified conditions and held con-
stant for subsequent exposures. Primary mouse mono-
clonal antibody (sc-966) and rabbit polyclonal antibody
(sc5621) to PML were purchased from SantaCruz and
used at a 1:500 dilution. Primary antibody to LMP1 was
purchased from BD Bioscience (#559898) and used at a
dilution of 1:500. Secondary antibodies that were
employed were Alexa Fluor 594 goat anti-mouse (Invi-
trogen #A11005), AlexaFluor 594 goat anti-rabbit (Invi-
trogen#A21207) and AlexaFluor 488 goat anti-mouse
(Invitrogen #A11008) and were as used at a dilution of
1:500.
Statistical Analysis
Individual comparisons were analyzed by two-tailed
unpaired t tests; multiple comparisons were analyzed by
ANOVA with Modified Bonferroni post hoc test. A p-
value < 0.05 was considered significant. For figures, (*)
denotes p < 0.05 compared to control, (**) denotes p <
0.01 compared to control, (***) denotes p < 0.001 com-
pared to control, (#) denotes p < 0.05 ATO compared to
ATO/GCV co-treatment, (###) denotes p < 0.001 ATO
compared to ATO/GCV co-treatment. The presented
data is representative of multiple experiments performed
in triplicate. Data is represented as the mean (+/-) SEM.
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